<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03741894</url>
  </required_header>
  <id_info>
    <org_study_id>7065-PTE 2018.</org_study_id>
    <nct_id>NCT03741894</nct_id>
  </id_info>
  <brief_title>Examination of the Prevention and Treatment Modalities of Alveolitis in Relation With Impacted Teeth Surgery</brief_title>
  <acronym>AITS</acronym>
  <official_title>Examination of the Prevention and Treatment Modalities of Alveolitis in Relation With Impacted Teeth Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pecs</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pecs</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      In the everyday clinical practice the incidence of minor complications is approximately
      15-20% of the total number of third molar removals. Alveolitis (dry socket syndrome) may
      arise in 30-40% of the surgical tooth removals. Several preventive approaches are known, such
      as the use of iodoform gauze, zink-oxide eugenol paste, platelet rich fibrin (PRF), different
      medicine containing pastes, like antibiotics containing, non-steroid pain killer containing,
      steroid containing, or the application of chlorhexidine gel and solutions. In the case of a
      manifest alveolitis these methods can be used as well. The aims of this research are: i) to
      identify the important pathogens which play role in the development of alveolitis
      (microbiological methods), ii) to analyze the in vitro effectivity of the different
      antiseptic materials in case of infections (inhibitory zones) iii) to compare the effectivity
      of different alveolitis preventive methods in a prospective clinical study, iv) to compare
      the different treatment options in alveolitis in a prospective clinical study.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2018</start_date>
  <completion_date type="Anticipated">September 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized controlled trial</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in minor postoperative complications (trismus)</measure>
    <time_frame>day of surgery, 3rd, 7th postoperative days</time_frame>
    <description>Measuring postoperative trismus (maximal mouth opening - inter-incisal distance in millimeters).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in minor postoperative complications (oedema)</measure>
    <time_frame>day of surgery, 3rd, 7th postoperative days</time_frame>
    <description>measuring postoperative oedema (flexible ruler- lateral canthus-mandibular angle distance in millimeters and tragus-labial commissure distance in millimeters).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in minor postoperative complications (pain)</measure>
    <time_frame>1st, 2nd, 3rd, 4th, 5th, 6th and 7th postoperative days</time_frame>
    <description>Measuring level of pain in Visual Analog Scale (minimum score is 0 which represents no pain, maximum score is 10 which shows the worst pain) postoperatively</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in necessity of postoperatively taken analgesics</measure>
    <time_frame>1st, 2nd, 3rd, 4th, 5th, 6th and 7th postoperative days</time_frame>
    <description>Registering dose of active agent of taken analgesics in milligrams .</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in necessity of postoperatively taken analgesics</measure>
    <time_frame>1st, 2nd, 3rd, 4th, 5th, 6th and 7th postoperative days</time_frame>
    <description>Registering number of daily repeats of taken analgesics.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Alveolitis of Jaw</condition>
  <condition>Alveoli, Teeth; Inflammation</condition>
  <condition>Dry Socket</condition>
  <condition>Impacted Third Molar Tooth</condition>
  <arm_group>
    <arm_group_label>Primary wound closure</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Routine primary wound closure with single interrupted sutures (Surgilon 3-0 non-absorbable) only.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Iodoform and wound closure</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients get iodoform (1000 grams containing 350 grams of iodoform, 300 grams of glycerin and 350 grams of alcohol 96%) soaked gauze (steril selvedge gauze bandage 2 cm x 5 m in appropriate length) drainage during suture (Surgilon 3-0 non-absorbable) placements for a week.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chlorhexidine and wound closure</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Extraction sockets are filled with 1% chlorhexidine gel (Curasept ADS310, Sager Pharma, Sager Dental Kft.,Budapest, Hungary) before suture (Surgilon 3-0 non-absorbable) placements.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Iodoform</intervention_name>
    <description>Patients get iodoform (1000 grams containing 350 grams of iodoform, 300 grams of glycerin and 350 grams of alcohol 96%) soaked gauze (steril selvedge gauze bandage 2 cm x 5 m in appropriate length) drainage during suture placements for a week.</description>
    <arm_group_label>Iodoform and wound closure</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Wound closure using sutures</intervention_name>
    <description>Routine primary wound closure with single interrupted sutures (Surgilon 3-0 non-absorbable) only.</description>
    <arm_group_label>Chlorhexidine and wound closure</arm_group_label>
    <arm_group_label>Iodoform and wound closure</arm_group_label>
    <arm_group_label>Primary wound closure</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chlorhexidine</intervention_name>
    <description>Extraction sockets are filled with 1% chlorhexidine gel (Curasept ADS310, Sager Pharma, Sager Dental Kft.,Budapest, Hungary) before suture (Surgilon 3-0 non-absorbable) placements.</description>
    <arm_group_label>Chlorhexidine and wound closure</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pell-Gregory II/B impaction

          -  mesioangular impactions

          -  tooth sectioning is not necessary for removal

          -  without local infection of third molar

        Exclusion Criteria:

          -  no general diseases or following treatments (DM, steroids, bleeding risk,
             chemotherapy, radiotherapy, bisphosphonates, immunosuppressive conditions)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Department of Oral and Maxillofacial Surgery, University of Pécs</name>
      <address>
        <city>Pécs</city>
        <zip>7621</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jozsef Szalma, DMD, PhD</last_name>
      <phone>+3672535924</phone>
      <email>drszalma@freemail.hu</email>
    </contact>
    <investigator>
      <last_name>Jozsef Szalma, DMD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Laszlo Vajta, DMD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Balázs Soós, DMD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kata Janovics, DMD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Hungary</country>
  </location_countries>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>October 30, 2018</study_first_submitted>
  <study_first_submitted_qc>November 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 15, 2018</study_first_posted>
  <last_update_submitted>November 12, 2018</last_update_submitted>
  <last_update_submitted_qc>November 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pecs</investigator_affiliation>
    <investigator_full_name>Balazs Soos</investigator_full_name>
    <investigator_title>DMD, Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>alveolitis</keyword>
  <keyword>iodoform</keyword>
  <keyword>chlorhexidine</keyword>
  <keyword>minor complications</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tooth, Impacted</mesh_term>
    <mesh_term>Dry Socket</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chlorhexidine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

